Buy KPV 10 mg in Australia
KPV 10 mg costs $84.99 in Australia from Australian Research Peptides, supplier to laboratories and researchers, but is out of stock for now. KPV is a dried, off-white tripeptide in a tamper-sealed vial: lysine, proline and valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied in inflammation research, where laboratories test it against PepT1, the transporter that lets it into cells, and against NF-kappaB and MAP kinase, switches that turn inflammation on. It is independently lab-tested. In vitro research purposes only.
Cell Signalling Research · Lyophilised Powder · Independently lab-tested · SKU 50663
$84.99
Presentation
10 mg per vial
Grade
Research Grade
Form
Lyophilised Powder
Category
Cell Signalling Research
Currently out of stock — stocked lines dispatch same business day before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
KPV · 10 mg
$84.99
In stock in the same research category: BPC-157 10 mg
KPV is out of stock. BPC-157 is in the same research category and is available now.
View BPC-157 10 mgBrowse all Cell Signalling Research
About KPV
Nearly all published KPV research sits in inflammation research. The best-covered strand is gastrointestinal, studied in human intestinal epithelial cell lines, a human T-cell line and two mouse models. Other papers used rodent models and cultured macrophages, or looked at signalling in cultured human keratinocytes. All of this is preclinical work in cells and animals.
KPV is short for Lys-Pro-Val, the three amino acids in the chain. They are the last three residues of alpha-melanocyte-stimulating hormone, which is thirteen residues long. That is why chemical databases index the tripeptide as alpha-MSH(11-13) and also as ACTH-(11-13). Adrenocorticotropic hormone comes from the same precursor protein, pro-opiomelanocortin, and carries the same three residues at that spot.
Australian Research Peptides lists KPV in a single strength as a freeze-dried powder, sealed in a tamper-evident glass vial. The powder is independently lab-tested before it is listed, including a check that confirms the molecule's identity. The material is a laboratory reference compound, and it is not an approved medicine in Australia.
Australian Research Peptides lists KPV in Australia as a single 10 mg vial, and it is searched as KPV, KPV peptide and by its database names alpha-MSH(11-13) and ACTH-(11-13). Stock is held locally and posted to every state and territory, so an order does not wait on an overseas consignment or an import step. The peptide is independently lab-tested before listing, and the CoA library sets out which strengths have a certificate published.
BAC water (bacteriostatic water) is also in our range.
The peptide calculator works out the mg/mL concentration of a reconstituted vial.
KPV specifications, storage and shipping
- Compound: KPV
- Also known as: KPV (Lys-Pro-Val; alpha-MSH 11-13)
- Class: Tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (50663)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: Research grade
- Testing: Independently lab-tested before release
- Identity confirmation: Mass spectrometry
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
KPV is independently lab-tested before release. No laboratory report is published for this line yet. The COA library lists every product and strength, and says which reports are available.
This line is currently out of stock. Stocked lines ordered before 12pm Sydney time on a business day are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about KPV
This question guide from Australian Research Peptides covers KPV in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
KPV is ordered from Australian Research Peptides, an Australian seller that posts it domestically, so a vial never passes through customs on its way to the bench. The tripeptide Lys-Pro-Val is listed in one strength, freeze-dried under a tamper-evident seal. Payment runs on PayID or bank transfer, with no wallets, instalment accounts or crypto. Weekday orders lodged before 12pm Sydney time are dispatched that same day once a vial is available, by Express Post if the work is urgent.
Reconstituting KPV means dissolving the dried tripeptide in a sterile laboratory diluent, sent down the side of the vial rather than straight onto the Lys-Pro-Val and swirled gently rather than shaken. Shaking whips air through and produces foam. Wait until the liquid runs clear. For storage, the solution can be divided into aliquots and frozen.
KPV takes 2–5 business days to arrive under standard tracked post and 1–2 under Express Post for much of Australia. If a parcel has not arrived or tracking has stalled, reporting it within seven days of the expected delivery date gives support the best chance of resolving it with the carrier. Keep the tracking number emailed at lodgement; any investigation starts from it.
A 10 mg KPV vial is normally dissolved in one step, because KPV is only three amino acids and goes into solution readily, and the volume added sets the concentration. The vial holds the peptide and nothing else, with no diluent or measuring equipment packed beside it.
KPV holds no approval from the Food and Drug Administration, and no country registers a KPV medicine. Melanocortin peptides are not uniformly unapproved as a class — afamelanotide reached the market — but this three-residue fragment of alpha-melanocyte-stimulating hormone has never been submitted anywhere. Its published work sits in cell lines and rodent models, which is where evidence starts rather than where a regulatory decision gets made.
Identity, names and exact format
KPV stands for Lys-Pro-Val, the short forms of lysine, proline and valine. Those are the standard three-letter abbreviations chemists use for amino acids. The letters run in sequence order, so lysine sits at one end and valine at the other. Written out in full, the same molecule is L-lysyl-L-prolyl-L-valine.
Published KPV research is preclinical, and nearly all of it sits in inflammation research. Dalmasso 2008 examined KPV in human intestinal and T-cell lines against NF-kappaB and MAP kinase signalling. The same team extended the work into two mouse models. Elliott 2004 reported that in cultured keratinocytes, the main cells of the skin surface, KPV raised intracellular calcium but not cyclic AMP. The published record stops there.
Three amino acids make up KPV, and that count is what the word tripeptide means. They are lysine, proline and valine, joined in that order. Alpha-MSH, the parent peptide, has thirteen, and KPV is its final three. Note that the number on the vial label is a mass of powder in milligrams, not a count of amino acids.
Both KPV and BPC-157 appear in gastrointestinal research but along different lines — KPV as a three-amino-acid piece of alpha-MSH examined against NF-kappaB and MAP kinase signalling, BPC-157 across a wider set of models and against blood-vessel growth and growth-factor pathways. BPC-157 has the broader literature; KPV's is the more narrowly focused of the two.
Research context and evidence
KPV is a short peptide — only three amino acids — that occurs naturally in the body as a fragment of a larger hormone governing immune responses. Published KPV research sits mostly in laboratory models of gut and skin inflammation, where the tripeptide is examined against specific pathways — NF-kappaB and MAP kinase signalling, and the PepT1 transporter — rather than through broad immune suppression. Australian Research Peptides does not restate outcomes from that work: KPV is supplied to laboratories and researchers for in vitro research only.
KPV crosses into cells through PepT1, a transporter that carries di- and tripeptides. PepT1 is expressed in the small intestine and is upregulated in colonic tissue in the inflammation models where gastrointestinal researchers first examined it. Inside the cell, KPV is studied against NF-kappaB and MAP kinase signalling. It appears not to require the melanocortin receptors its parent hormone binds.
Most published KPV research is gut research, carried out in cultured human intestinal cell lines, a human T-cell line and two chemically induced mouse models of colon inflammation. That work examines KPV against NF-kappaB and MAP kinase signalling and against PepT1, the transporter that carries the tripeptide into intestinal cells. None of it is a study in people, and Australian Research Peptides sells KPV to laboratories and researchers for in vitro work only.
A KPV vial holds one substance: dried lysine-proline-valine, and nothing else. There is no second peptide, no blend partner and no liquid. The mass of powder is printed on the label. Those three amino acids sit in glass under a tamper-evident seal. KPV is a single-compound listing, not a multi-peptide blend.
KPV has no published pharmacokinetic profile of any kind: no half-life, no clearance figure, nothing. Its evidence base is cell and rodent work, and cultured cells are a system where circulation and elimination do not exist as concepts. Short peptides are widely expected to disappear quickly, but an expectation about a class is not a measurement of this tripeptide, and any duration quoted for it came from a seller rather than a laboratory.
Mouse gastrointestinal models are the best-covered corner of the KPV literature, alongside cultured human intestinal epithelial lines and a human T-cell line. Readouts reported include tissue histology and myeloperoxidase activity in colonic tissue. Every one of these is a laboratory or animal system, and nothing in them establishes anything about a person.
KPV is paid for by PayID or bank transfer. If a KPV payment is going to be late, contact support before the window closes rather than after. The reservation lapses automatically at the deadline and the stock is released, and on a line that is frequently unavailable there is no guarantee it can be re-reserved.
A KPV stock alert fires once and is then finished — there is nothing to unsubscribe from afterwards, because the record exists only until the message is sent. Registering again after that is what re-arms it, which matters on a line that can go unavailable more than once.
KPV, BPC-157 and TB-500 appear together with GHK-Cu in Australian Research Peptides’ 80 mg KLOW blend. Buying them as separate vials allows each to be varied independently; KLOW fixes the ratio and reconstitutes as one. No published study has tested either arrangement.
KPV is a three-amino-acid peptide, as short as anything in this range, and ten milligrams of it dries into a sparse dust genuinely difficult to see through glass. Judging quantity by eye fails badly at that scale. Tilt the container and watch instead for loose particles moving. Very small peptides also tend to spread up the sides rather than settling as one neat deposit.
Handling, storage and measurements
A 10 mg KPV vial has no single correct volume and Australian Research Peptides publishes none. KPV is only three amino acids and dissolves readily, so it is not a compound that needs coaxing into solution. The volume added changes the concentration, never the 10 mg of peptide in the glass.
KPV takes up water without much resistance, so early cloudiness is nearly always the air that mixing introduced, seen as fine bubbles gathered near the surface. They clear on their own. Contents taken straight from a freezer behave similarly until warm. Where a KPV preparation is still not transparent after ten minutes standing, undissolved material or aggregation is the realistic explanation.
KPV ships as a dry tripeptide and needs a diluent before bench work, usually an aqueous one. The glass holds Lys-Pro-Val on its own, with no second powder and no liquid. Diluent is the name given to whatever a dried compound is taken up in.
Australian Research Peptides, trading name ARP, is the Australian supplier of KPV, sending it from a local address to buyers in every state and territory. Delivery goes by tracked post, with Express Post there when a result is waiting on it. KPV, the three-residue tail of alpha-MSH, is listed in one strength.
KPV comes in one strength only, so a single Australian-dollar figure per vial covers everything Australian Research Peptides sells under that name. The amount, and whether a vial can ship immediately, are both held as live catalogue data rather than fixed in prose. KPV is listed as a research peptide, which is how Australian Research Peptides separates it from a consumable or a supply item.
Three KPV vials are needed for free Standard tracked post and four for the Express Post waiver. KPV is also often ordered alongside BPC-157 for gut work, which reaches the free-post threshold faster than ordering KPV alone. Qualification is judged on the goods subtotal, before any discount code.
KPV is listed out of stock at Australian Research Peptides in its single 10 mg strength; the alert on this page is what tells a buyer when it returns. With one strength there is one Australian-dollar figure per vial, shown above rather than repeated in this answer. Every parcel is posted within Australia, and the certificate position for each listing is set out in ARP's CoA library.
KPV is bought online from Australian Research Peptides, which lists the tripeptide in one strength and keeps its availability current. Payment settles by PayID or bank transfer into the company's account; wallet and crypto options do not exist. Delivery is by post inside Australia, from Sydney, so a KPV vial is never presented to customs.
Testing and batch documents
KPV is not the same as alpha-MSH; it is only the hormone's last three amino acids. Alpha-melanocyte-stimulating hormone runs thirteen amino acids long, and KPV covers positions eleven to thirteen. The two also behave differently in the laboratory. Getting 2003 found that in cultured macrophages — immune cells grown in dishes — alpha-MSH suppressed the cells' activation, their switch into an inflammatory state, while KPV did not. Research on the full-length hormone is therefore not research on the tripeptide.
KPV and BPC-157 are different sizes and come from different parents. KPV is three amino acids clipped off alpha-MSH, and PubChem puts the free peptide near 342 g/mol. It records BPC-157 at about 1,419 g/mol, roughly four times heavier. Their literatures overlap in gut research and separate elsewhere.
Ordering, payment and Australian delivery
KPV lacks all five amino acids that Bachem singles out as unstable in solution. Its guide names asparagine, glutamine, cysteine, methionine and tryptophan as the risky ones. KPV has only lysine, proline and valine. Even so, keep the sealed powder dry and below -15 °C, and let the vial reach room temperature before opening, because it draws in moisture.
KPV is not an approved medicine in Australia. It does not appear on the Australian Register of Therapeutic Goods, so the TGA has not assessed it for safety, quality or effectiveness. Australian Research Peptides supplies KPV as a laboratory reference compound and makes no medical claim about it. The TGA publishes guidance for anyone importing or supplying unapproved peptide products.
KPV has no named entry on the WADA Prohibited List of substances banned in sport, but category S0 covers any substance with no current approval as a medicine anywhere, and no regulator has approved KPV. So the absence of a named entry does not mean KPV is permitted. Sport Integrity Australia is the Australian authority on that list.
KPV does not appear on the Australian Register of Therapeutic Goods, which means the TGA has never assessed it for safety, quality or effectiveness. An importer is therefore not bringing in a rejected product but an unexamined one, and the unapproved-goods rules cover it either way. The TGA publishes guidance for anyone importing peptides. An Australian Research Peptides order is domestic and imports nothing.
Access and regulatory questions
A KPV batch is independently lab-tested before it goes anywhere, and mass spectrometry confirms the molecule is the three-residue peptide rather than full-length alpha-MSH. Those two differ by ten amino acids, so the gap in mass is wide and easy to read. No matching certificate is currently published for this product and strength.
KPV testing settles chain length much better than it settles residue order. Mass spectrometry separates the tripeptide from alpha-MSH outright, since the two masses are nowhere near each other. It cannot tell lysine-proline-valine from those same three amino acids arranged differently. KPV is supplied to laboratories and researchers for in vitro research purposes only.
KPV is also known as Lys-Pro-Val, lysyl-prolyl-valine and, spelled out fully, L-lysyl-L-prolyl-L-valine. Because those same three residues close two pro-opiomelanocortin hormones, databases file the tripeptide as alpha-MSH(11-13) and ACTH-(11-13), under CAS 67727-97-3. None of them names a different compound.
KPV is catalogued in one size only, a 10 mg vial, and there is no microgram-sized listing. The units sit a thousand apart: 10 mg of dried Lys-Pro-Val is 10,000 micrograms. The label and the listing give only the total mass of KPV sealed in the vial.